Suppr超能文献

前列腺特异性激肽释放酶相关肽酶及其与前列腺癌生物学和检测的关系。已确立的相关性和新出现的作用。

Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles.

机构信息

Hans Lilja, MD, PhD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave Box 213, New York, NY 10065, USA, Tel.: +1 212 639 6982, Fax: +1 646 422 2379, E-mail:

出版信息

Thromb Haemost. 2013 Sep;110(3):484-92. doi: 10.1160/TH13-04-0275. Epub 2013 Aug 1.

Abstract

Kallikreins are a family of serine proteases with a range of tissue-specific and essential proteolytic functions. Among the best studied are the prostate tissue-specific KLK2 and KLK3 genes and their secreted protease products, human kallikrein 2, hk2, and prostate-specific antigen (PSA). Members of the so-called classic kallikreins, these highly active trypsin-like serine proteases play established roles in human reproduction. Both hK2 and PSA expression is regulated by the androgen receptor which has a fundamental role in prostate tissue development and progression of disease. This feature, combined with the ability to sensitively detect different forms of these proteins in blood and biopsies, result in a crucially important biomarker for the presence and recurrence of cancer. Emerging evidence has begun to suggest a role for these kallikreins in critical vascular events. This review discusses the established and developing biological roles of hK2 and PSA, as well as the historical and advanced use of their detection to accurately and non-invasively detect and guide treatment of prostatic disease.

摘要

激肽释放酶是一族丝氨酸蛋白酶,具有多种组织特异性和重要的蛋白水解功能。其中研究得最多的是前列腺组织特异性 KLK2 和 KLK3 基因及其分泌的蛋白酶产物,人激肽释放酶 2(hk2)和前列腺特异性抗原(PSA)。这些所谓的经典激肽释放酶成员是高度活跃的胰蛋白酶样丝氨酸蛋白酶,在人类生殖中发挥着既定的作用。hK2 和 PSA 的表达均受雄激素受体调控,雄激素受体在前列腺组织发育和疾病进展中起着至关重要的作用。这一特征,加上能够在血液和活检中灵敏地检测到这些蛋白质的不同形式,使它们成为癌症存在和复发的重要生物标志物。新出现的证据开始表明这些激肽释放酶在关键的血管事件中发挥作用。本文讨论了 hK2 和 PSA 的既定和不断发展的生物学作用,以及它们的检测在准确和非侵入性地检测和指导前列腺疾病治疗方面的历史和先进应用。

相似文献

3
Kallikreins as biomarkers for prostate cancer.激肽释放酶作为前列腺癌的生物标志物。
Biomed Res Int. 2014;2014:526341. doi: 10.1155/2014/526341. Epub 2014 Apr 7.

引用本文的文献

3
Novel radionuclide therapy combinations in prostate cancer.前列腺癌中的新型放射性核素治疗组合
Ther Adv Med Oncol. 2023 Aug 2;15:17588359231187202. doi: 10.1177/17588359231187202. eCollection 2023.

本文引用的文献

1
Cancer statistics, 2013.癌症统计数据,2013 年。
CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.
2
Prostate cancer: ESMO Consensus Conference Guidelines 2012.前列腺癌:ESMO 共识会议指南 2012 年版。
Ann Oncol. 2013 May;24(5):1141-62. doi: 10.1093/annonc/mds624. Epub 2013 Jan 9.
3
Risk stratification in prostate cancer screening.前列腺癌筛查中的风险分层。
Nat Rev Urol. 2013 Jan;10(1):38-48. doi: 10.1038/nrurol.2012.225. Epub 2012 Dec 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验